Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Novartis Reports Updated Results from Kymriah's JULIET Study

Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.

    Ryan McQueeney headshot

    Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today

    Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.

      The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics

      The Zacks Analyst Blog Highlights: Bank of America, Celgene, Goldman Sachs, L Brands and Quest Diagnostics

        Gilead Sciences to Acquire Cell Design Labs for $567 Million

        Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.

          Sanofi Begins Combo Studies on Multiple Myeloma Candidate

          Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.

            Why Is Celgene (CELG) Up 3.4% Since the Last Earnings Report?

            Celgene (CELG) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              CAR-T Therapy Space 2017 Progress Report

              Given the vast potential of the CAR T therapy space and two recent approvals, biotech companies are leaving no stone unturned to develop their pipeline candidates.

                J&J Seeks Darzalex's Label Expansion in First-Line Setting

                Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

                  FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

                    Agios Posts New Data on Glioma Candidate from Dose Expansion

                    Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.

                      Celgene CAR-T Therapy Gets Breakthrough Therapy Designation

                      FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.

                        The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP

                        The Zacks Analyst Blog Highlights: Facebook, Celgene, BlackRock, Danaher and BP

                          Mark Vickery headshot

                          Top Stock Reports for Facebook, Celgene & BlackRock

                          Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Celgene (CELG) and BlackRock (BLK).

                            Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised

                            Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.

                              Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

                              Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts

                                It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.

                                  Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?

                                  Agios' (AGIO) only marketed drug Idhifa that looks effective to cure patients with relapsed or refractory acute myeloid leukemia might drive the company's earnings in Q3.

                                    Busiest Day Of The Q3 Earnings Season

                                    Busiest Day Of The Q3 Earnings Season

                                      Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View

                                      Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.

                                        Mark Vickery headshot

                                        Tall Data in Short Time

                                        Plenty of S&P 500 companies have already reported earnings before the opening bell today, and if that's not enough, we've also got tons of economic data and newsworthy financial information to get to.

                                          Ekta Bagri headshot

                                          Celgene (CELG) Beats on Q3 Earnings, Misses Sales

                                          Celgene (CELG) beat on third-quarter 2017 earnings but revenues missed expectations.

                                            Is Celgene (CELG) Poised for a Beat This Earnings Season?

                                            Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.

                                              Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

                                              Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.

                                                Arpita Dutt headshot

                                                Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider

                                                Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?

                                                  Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval

                                                  Gilead (GILD) wins the FDA approval for its CAR-T therapy, Yescarta, for treating refractory aggressive non-Hodgkin lymphoma.